Distinct autoantibody profiles across checkpoint inhibitor types and toxicities

References

• Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med. 2013;368(14):1365–8. doi:10.1056/NEJMc1302338.
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Cho BC, Ou X, Walding A, Dymond AW, Ren S, Cantarini M, Jänne PA. Osimertinib plus durvalumab in patients with EGFR-Mutated, advanced NSCLC: a phase 1b, open-label, multicenter trial. J Thorac Oncol. 2022;17(5):718–723. doi:10.1016/j.jtho.2022.01.012.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, Hochmair MJ, Powell SF, Bischoff HG, Peled N. et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-Cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992–1998. doi:10.1200/JCO.22.01989.
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526–1533. doi:10.1056/NEJMoa021933.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Chan KK, Jivanelli B, Bass AR. Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: a systematic literature review. J Clin Rheumatol. 2022;28(2):e498–e505. doi:10.1097/RHU.0000000000001777.
   PubMed Web of Science ®Google Scholar
• de Moel EC, Rozeman EA, Kapiteijn EH, de Moel EC, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D. Autoantibody development under treatment with immune-checkpoint inhibitors. Cancer Immunol Res. 2019;7(1):6–11. doi:10.1158/2326-6066.CIR-18-0245.
   PubMed Web of Science ®Google Scholar
• Gowen MF, Giles KM, Simpson D, Tchack J, Zhou H, Moran U, Dawood Z, Pavlick AC, Hu S, Wilson MA. et al. Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors. J Transl Med. 2018;16(1):82. doi:10.1186/s12967-018-1452-4.
   PubMedGoogle Scholar
• Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K. et al. Profiling preexisting antibodies in patients treated with anti–PD-1 therapy for advanced non–small cell lung cancer. JAMA Oncol. 2019;5(3):376–383. doi:10.1001/jamaoncol.2018.5860.
   PubMed Web of Science ®Google Scholar
• Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, Fenske TS, Barta SK, Palmisiano ND. et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020;7(9):e660–e670. doi:10.1016/S2352-3026(20)30221-0.
   PubMed Web of Science ®Google Scholar
• Ghosh N, Postow M, Zhu C, Jannat-Khah D, Li Q-Z, Vitone G, Chan KK, Bass AR. Lower baseline autoantibody levels are associated with immune-related adverse events from immune checkpoint inhibition. J Immunother Cancer. 2022;10(1):e004008. doi:10.1136/jitc-2021-004008.
   PubMed Web of Science ®Google Scholar
• Li QZ, Zhou J, Wandstrat AE, Carr-Johnson F, Branch V, Karp DR, Mohan C, Wakeland EK, Olsen NJ. Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes. Clin Exp Immunol. 2007;147(1):60–70. doi:10.1111/j.1365-2249.2006.03251.x.
   PubMed Web of Science ®Google Scholar
• Lee EC, Whitehead AL, Jacques RM, Julious SA. The statistical interpretation of pilot trials: should significance thresholds be reconsidered? BMC Med Res Methodol. 2014;14(1):41. doi:10.1186/1471-2288-14-41.
   PubMed Web of Science ®Google Scholar
• Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J. et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci USA. 2019;116(44):22246–22251. doi:10.1073/pnas.1908079116.
   PubMed Web of Science ®Google Scholar
• Barth DA, Stanzer S, Spiegelberg J, Bauernhofer T, Absenger G, Posch F, Lipp R, Halm M, Szkandera J, Balic M. et al. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: a prospective longitudinal pan-cancer study. Cancer Med. 2022;11(16):3074–3083. doi:10.1002/cam4.4675.
   PubMed Web of Science ®Google Scholar
• Johannet P, Liu W, Fenyo D Wind-Rotolo, M., Krogsgaard, M., Mehnert, J.M., Weber, J.S., Zhong, J. and Osman, I. Baseline serum autoantibody signatures predict recurrence and toxicity in melanoma patients receiving adjuvant immune checkpoint blockade. Clin Cancer Res. 2022;28(18):4121–4130. doi:10.1158/1078-0432.CCR-22-0404.
   PubMed Web of Science ®Google Scholar
• Hossen MM, Ma Y, Yin Z, Xia Y, Du J, Huang JY, Huang JJ, Zou L, Ye Z, Huang Z. et al. Current understanding of CTLA-4: from mechanism to autoimmune diseases. Front Immunol. 2023;14:1198365. doi:10.3389/fimmu.2023.1198365.
   PubMedGoogle Scholar
• Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. 2010;236:219–242. doi:10.1111/j.1600-065X.2010.00923.x.
   PubMed Web of Science ®Google Scholar
• Yang Y, Li X, Ma Z, Wang C, Yang Q, Byrne-Steele M, Hong R, Min Q, Zhou G, Cheng Y. et al. CTLA-4 expression by B-1a B cells is essential for immune tolerance. Nat Commun. 2021;12(1):525. doi:10.1038/s41467-020-20874-x.
   PubMed Web of Science ®Google Scholar
• Wei SC, Sharma R, Anang NAS, Levine JH, Zhao Y, Mancuso JJ, Setty M, Sharma P, Wang J, Pe’er D. et al. Negative Co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states. Immunity. 2019;50(4):1084–1098 e10. doi:10.1016/j.immuni.2019.03.004.
   PubMed Web of Science ®Google Scholar
• Pereira RS, Black CM, Duance VC, Jones VE, Jacoby RK, Welsh KI. Disappearing collagen antibodies in rheumatoid arthritis. Lancet. 1985;326(8453):501–502. doi:10.1016/s0140-6736(85)90436-2.
   Google Scholar
• Imoto K, Kohjima M, Hioki T, Kurashige T, Kurokawa M, Tashiro S, Suzuki H, Kuwano A, Tanaka M, Okada S. et al. Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patients. Can J Gastroenterol Hepatol. 2019;2019:1–12. doi:10.1155/2019/6391712.
   Web of Science ®Google Scholar
• Reschke R, Shapiro JW, Yu J, Rouhani SJ, Olson DJ, Zha Y, Gajewski TF. Checkpoint blockade–induced dermatitis and colitis are dominated by tissue-resident memory T cells and Th1/Tc1 cytokines. Cancer Immunol Res. 2022;10(10):1167–1174. doi:10.1158/2326-6066.CIR-22-0362.
   PubMed Web of Science ®Google Scholar
• Yeo AL, Kandane-Rathnayake R, Koelmeyer R, Golder V, Louthrenoo W, Chen Y-H, Cho J, Lateef A, Hamijoyo L, Luo S-F. et al. SMART-SLE: serology monitoring and repeat testing in systemic lupus erythematosus—an analysis of anti-double-stranded DNA monitoring. Rheumatology (Oxford). 2024;63(2):525–533. doi:10.1093/rheumatology/kead231.
   PubMed Web of Science ®Google Scholar
• Meneghini M, Bestard O, Grinyo JM. Immunosuppressive drugs modes of action. Best Pract Res Clin Gastroenterol. 2021;54-55:101757. doi:10.1016/j.bpg.2021.101757.
   PubMed Web of Science ®Google Scholar
• Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. N Engl J Med. 2005;353(16):1711–1723. doi:10.1056/NEJMra050541.
   PubMed Web of Science ®Google Scholar
• Leiferman KM, Snook JP, Khalighi MA, Kuechle MK, Zone JJ. Diagnostics for dermatologic diseases with autoantibodies. J Appl Lab Med. 2022;7(1):165–196. doi:10.1093/jalm/jfab147.
   PubMedGoogle Scholar
• Pelosof LC, Gerber DE. Paraneoplastic syndromes: an approach to diagnosis and treatment. Mayo Clin Proc. 2010;85(9):838–854. doi:10.4065/mcp.2010.0099.
   PubMed Web of Science ®Google Scholar
• Khan S, von Itzstein MS, Lu R, Bermas BL, Karp DR, Khan SA, Fattah FJ, Park JY, Saltarski JM, Gloria-McCutchen Y. et al. Late-onset immunotherapy toxicity and delayed autoantibody changes: checkpoint inhibitor–induced Raynaud’s-like phenomenon. Oncologist. 2020;25(5):e753–e757. doi:10.1634/theoncologist.2019-0666.
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Bartlett NL, Berryman RB, Chen R, Matous JV, Fanale MA, O’Connor OA, Olshefski R, Smith SE, Huebner D. et al. Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies. Leuk Lymphoma. 2015;56(4):1151–1153. doi:10.3109/10428194.2014.951843.
   PubMed Web of Science ®Google Scholar
• Wu J, Hong D, Zhang X, Lu X, Miao J. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Sci Rep. 2017;7(1):44173. doi:10.1038/srep44173.
   PubMedGoogle Scholar
• Fu J, Li WZ, McGrath NA, Lai CW, Brar G, Xiang Y-Q, Xie C. Immune checkpoint inhibitor associated hepatotoxicity in primary liver cancer versus other cancers: a systematic review and meta-analysis. Front Oncol. 2021;11:650292. doi:10.3389/fonc.2021.650292.
   PubMed Web of Science ®Google Scholar